« Return to News | Drug Sponsors

BioLineRx licenses Hepatitis C treatment to CCTQ

Tuesday, June 11, 2013 12:00 PM

Drug development company BioLineRx has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical (CCTQ), a Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an oral treatment for the Hepatitis C virus (HCV).

"Unfortunately, the prevalence of HCV is relatively significant in China, with reports of 3.2% of the population (approximately 43 million individuals) suffering from this chronic and debilitating disease,” said Jian Sun Emba, CTTQ president. “Thus, there is a clear and urgent need to develop new, safe and effective treatments for HCV patients in China."

BioLineRx will grant CTTQ exclusive rights to develop, manufacture and commercialize BL-8030 in China and Hong Kong. CTTQ will pay BioLineRx an upfront license fee, plus future development, regulatory and commercialization milestones, for $30 million.

BioLineRx also has single-digit royalties on future sales of the drug and will retain the right to develop and commercialize BL-8030 in other parts of the world. BioLineRx will have access to development and regulatory data generated by CTTQ, as well as the right to use the data for commercialization and regulatory purposes outside China and Hong Kong.

"In parallel to collaborating with CTTQ to advance the drug, we intend to continue discussions with relevant partners for this project in other parts of the world," said Kinneret Savitsky, BioLineRx chief executive officer.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.